Transactions
11
Insider / SUPERNUS PHARMACEUTICALS, INC.
Horich William Todd
SVP, Commercial Operations at SUPERNUS PHARMACEUTICALS, INC.
- Ticker
- SUPN
- First filing on record
- March 10, 2026
- Latest trade on record
- March 10, 2026
- SEC filings
- EDGAR ↗
Horich William Todd, SVP, Commercial Operations at SUPERNUS PHARMACEUTICALS, INC., has disclosed 11 transactions in SUPN since March 10, 2026: 0 purchases (0 open-market buys) and 5 sales, worth about $673K at the reported prices. The latest was filed March 10, 2026, 4 days after the trade.
Open-market buys
0
Sales
5
Avg. disclosure lag
3.4d
Trading in charts
Trade timeline
When does this person trade, how big, and in which direction? Every trade in the last 12 months.
Bought (above the line)Sold (below the line)Other transaction
In the last 12 months Horich William Todd made no purchases and 5 sales worth $673K, plus 6 other transactions. Dot size is the dollar amount.
Portfolio mix
Which stocks does this person trade most? Tile size is dollars traded, all time on record.
Horich William Todd has traded 1 stock on record; the largest by dollars is SUPN.
What kind of transactions
Most Form 4 rows are pay arriving or tax being withheld, not a decision to buy or sell. Only code P is an open-market purchase and code S an open-market sale. What each code means: Form 4 transaction codes.
| Code | Meaning | Rows | Shares | Value |
|---|---|---|---|---|
| M | Option exercise or conversion | 6 | 15,000 | — |
| F | Shares withheld for tax | 3 | 3,455 | $189K |
| S | Open-market sale | 2 | 8,877 | $484K |
| Year | Rows | Bought | Sold |
|---|---|---|---|
| 2026 | 11 | 0 | 5 · $673K |
Transactions
| Security | Side | Trade date | Disclosed | Lag | Shares | Price | Value | Flags | Source | Share |
|---|---|---|---|---|---|---|---|---|---|---|
| SUPN | Option / conversion M | March 6, 2026 | March 10, 2026 | 4d | 1,125 | — | — | derivative | Form 4 ↗ | |
| SUPN | Option / conversion M | March 6, 2026 | March 10, 2026 | 4d | 3,750 | — | — | derivative | Form 4 ↗ | |
| SUPN | Option / conversion M | March 6, 2026 | March 10, 2026 | 4d | 2,625 | — | — | derivative | Form 4 ↗ | |
| SUPN | Sell S | March 10, 2026 | March 10, 2026 | 0d | 4,439 | $55 | $244K | Form 4 ↗ | ||
| SUPN | Sell S | March 9, 2026 | March 10, 2026 | 1d | 4,438 | $54 | $240K | Form 4 ↗ | ||
| SUPN | Sell F | March 6, 2026 | March 10, 2026 | 4d | 521 | $55 | $29K | Form 4 ↗ | ||
| SUPN | Option / conversion M | March 6, 2026 | March 10, 2026 | 4d | 1,125 | — | — | Form 4 ↗ | ||
| SUPN | Sell F | March 6, 2026 | March 10, 2026 | 4d | 1,718 | $55 | $94K | Form 4 ↗ | ||
| SUPN | Option / conversion M | March 6, 2026 | March 10, 2026 | 4d | 3,750 | — | — | Form 4 ↗ | ||
| SUPN | Sell F | March 6, 2026 | March 10, 2026 | 4d | 1,216 | $55 | $67K | Form 4 ↗ | ||
| SUPN | Option / conversion M | March 6, 2026 | March 10, 2026 | 4d | 2,625 | — | — | Form 4 ↗ |
Filings
| Filed | Form | Accession | Rows | Status | Source |
|---|---|---|---|---|---|
| March 10, 2026 | Form 4 | 0002117599-26-000004 | 11 | published | EDGAR ↗ |
Other insiders at SUPERNUS PHARMACEUTICALS, INC.
- Bhatt Padmanabh P. Sr. VP of IP, CSO 44 rows
- Khattar Jack A. President, CEO 33 rows
- Mottola Frank SVP, Chief Tech. Ops. Officer 29 rows
- DEC TIMOTHY C Senior Vice-President & CFO 26 rows
- Rubin Jonathan SVP, Chief Medical Officer 18 rows
- GEMAYEL GEORGES Director 10 rows
- NEWHALL CHARLES W III Director 8 rows
- Hudson Frederick M. Director 7 rows
- Sensenig Bethany Director 6 rows
- Barlow Carrolee Director 4 rows
Everyone on file, with contracts and lobbying under the company's name: SUPERNUS PHARMACEUTICALS, INC..
Guides for this page
- What is SEC Form 4? Who files: officers, directors and owners of more than 10% of a class of the company's shares.
- Form 4 transaction codes P = purchase. S = sale. These are the two market trades.
- Insider buying vs insider selling Selling outweighs buying by a wide margin in normal times.
- Options and derivatives on Form 4 Table I = shares. Table II = options and other derivatives.
- What disclosure data cannot tell you Filings are late by design: up to 45 days for Congress, two business days for insiders.
Sources and method
| Source | Filings | Rows | First filed | Newest filed | Read the originals |
|---|---|---|---|---|---|
| SEC EDGAR, Form 4 | 1 | 11 | March 10, 2026 | March 10, 2026 | Form 4 list on EDGAR |
Site built October 27, 2026. Every row in the tables above links to its own filing. To quote a figure, use the Cite button at the top of the page; see how to cite and reuse.
Every row comes from the reporting owner's Form 4 as filed with the SEC (EDGAR ownership XML), read daily. "Value" is shares × the reported price; code P is an open-market purchase, S a sale, M an option exercise, A a grant. The lag is the filing date minus the trade date; Form 4 is due within two business days. Amendments (4/A) are not merged. Details on the methodology page; report an error on corrections.
Not investment advice. Figures are public disclosures shown as filed; they may lag the trade and may be amended later. No recommendation is made or implied.